GlassScriptPhysician profile
Masha Mobbley
NPI 1063862605
$5,814.59
in general payments reported to CMS, 2019-2025
23 companies · $1,328 in 2025
The $1,328 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $394 · 2022: $826 · 2023: $1,420 · 2024: $1,846 · 2025: $1,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,025 · Education: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,025.17 |
| Education | $568.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,693.77 | 2021-2025 | |
| Janssen Biotech, INC. | $905.12 | 2021-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $751.98 | 2022-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $391.39 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $331.77 | 2021-2025 | Taltz, Ebglyss, Zepbound |
| Novartis Pharmaceuticals Corporation | $295.97 | 2022-2025 | |
| Incyte Corporation | $293.75 | 2022-2025 | Opzelura |
| Genzyme Corporation | $221.22 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $173.21 | 2024 | |
| Leo Pharma INC. | $98.34 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $97.14 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $90.63 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Arcutis Biotherapeutics, INC. | $83.74 | 2024-2025 | Zoryve |
| Amgen INC. | $80.24 | 2023-2024 | Otezla, Enbrel |
| Sanofi-Aventis U.S. LLC | $64.95 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $60.96 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $51.29 | 2021 | |
| Pfizer INC. | $35.58 | 2023 | |
| Biocon Biologics INC | $22.17 | 2025 | Yesintek |
| Organogenesis INC. | $19.78 | 2025 | Cygnus Dual |
| Dermavant Sciences, INC. | $18.28 | 2024 | Vtama |
| Strata Skin Sciences, INC. | $16.74 | 2021 | |
| Biofrontera INC. | $16.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masha Mobbley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.